|AxoGen Inc -- USA Stock|| |
USD 26.2 0.25 0.95%
Co-Founder and VP
Mr. John P. Engels is Vice President of AxoGen, Inc., since September 30, 2011. He is a cofounder of AC and has served as ACs Vice President since June 2006, having provided operational and financial leadership and managing AxoGens strategic and product development partnerships until January 2012 when he assumed the leadership of international sales. From 1999 to 2002, Mr. Engels worked as a consultant for the University of Florida, Saffron Hill Ventures and PA Early Stage Partners, among other companies. From 1993 to 1997, Mr. Engels was an analyst and associate at CACM, a boutique investment banking firm. Mr. Engels is currently a member of the board of directors of Oxicool, Inc., a privatelyheld company developing new cooling technologies
Age: 44 Founder Since 2011 MBA
Engels holds a MBA in Management and Operations from the Wharton School of Business at the University of Pennsylvania, and a BA from the University of Chicago.
The company has return on total asset (ROA)
of (14.34) %
which means that it has lost $14.34 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (195.07) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 24.17 M in liabilities with Debt to Equity (D/E) ratio of 213.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AxoGen Inc has Current Ratio of 3.6 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
AxoGen, Inc. operates as a medical technology company. AxoGen Inc (AXGN) is traded on Nasdaq Capital Markets in USA. It is located in FLORIDA, U.S.A and employs 113 people. AxoGen is listed under Medical Equipment category by Fama And French industry classification.